Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Contrast-enhanced ultrasound to visualize hemodynamic changes after rodent spinal cord injury.

Khaing ZZ, Cates LN, DeWees DM, Hannah A, Mourad P, Bruce M, Hofstetter CP.

J Neurosurg Spine. 2018 Jun 15:1-8. doi: 10.3171/2018.1.SPINE171202. [Epub ahead of print]

PMID:
29905521
2.

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.

Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA.

Clin Cancer Res. 2018 Apr 4. doi: 10.1158/1078-0432.CCR-17-3059. [Epub ahead of print]

PMID:
29618616
3.

Identification and characterisation of Staphylococcus aureus on low cost screen printed carbon electrodes using impedance spectroscopy.

Ward AC, Hannah AJ, Kendrick SL, Tucker NP, MacGregor G, Connolly P.

Biosens Bioelectron. 2018 Jul 1;110:65-70. doi: 10.1016/j.bios.2018.03.048. Epub 2018 Mar 22.

4.

A technique for K-wire assisted closed reduction and percutaneous screw fixation of phalangeal fractures.

Hannah A, Helm R.

Ann R Coll Surg Engl. 2018 May;100(5):419-420. doi: 10.1308/rcsann.2017.0206. Epub 2017 Nov 28. No abstract available.

PMID:
29181998
5.

Tension band wire stabilisation: an aid to femoral intramedullary nail fixation.

Hannah A, Bruce A.

Ann R Coll Surg Engl. 2018 May;100(5):420. doi: 10.1308/rcsann.2017.0207. Epub 2017 Nov 28. No abstract available.

PMID:
29181997
6.

Dental occlusion and temporomandibular disorders.

Stone JC, Hannah A, Nagar N.

Evid Based Dent. 2017 Oct 27;18(3):86-87. doi: 10.1038/sj.ebd.6401258.

PMID:
29075035
7.

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.

Lenz HJ, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L, Bondarde S, Dobbs T, Tagliaferri M, Hoch U, Hannah AL, Berkowitz M.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1161-1169. doi: 10.1007/s00280-017-3438-y. Epub 2017 Oct 17.

PMID:
29043412
8.

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch U, Tagliaferri M, Hannah AL, Garcia AA.

Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19.

PMID:
28935273
9.

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Nov;166(1):327-328. doi: 10.1007/s10549-017-4482-3. No abstract available.

PMID:
28884461
10.

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13. Erratum in: Breast Cancer Res Treat. 2017 Nov;166(1):327-328.

11.

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ.

Br J Haematol. 2017 Jul;178(1):112-118. doi: 10.1111/bjh.14727. Epub 2017 Apr 26.

PMID:
28444784
12.

Contrast-enhanced ultrasound imaging in vivo with laser-activated nanodroplets.

Yoon H, Yarmoska SK, Hannah AS, Yoon C, Hallam KA, Emelianov SY.

Med Phys. 2017 Jul;44(7):3444-3449. doi: 10.1002/mp.12269. Epub 2017 May 16.

PMID:
28391597
13.

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.

14.

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Shore T, Iacobelli M, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ; Defibrotide Study Group.

Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8.

15.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

16.

Blinking Phase-Change Nanocapsules Enable Background-Free Ultrasound Imaging.

Hannah AS, Luke GP, Emelianov SY.

Theranostics. 2016 Jul 25;6(11):1866-76. doi: 10.7150/thno.14961. eCollection 2016.

17.

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.

Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J.

Springerplus. 2016 Jul 8;5(1):1033. doi: 10.1186/s40064-016-2446-4. eCollection 2016.

18.

Super-Resolution Ultrasound Imaging in Vivo with Transient Laser-Activated Nanodroplets.

Luke GP, Hannah AS, Emelianov SY.

Nano Lett. 2016 Apr 13;16(4):2556-9. doi: 10.1021/acs.nanolett.6b00108. Epub 2016 Apr 5.

19.

Climate confusion among U.S. teachers.

Plutzer E, McCaffrey M, Hannah AL, Rosenau J, Berbeco M, Reid AH.

Science. 2016 Feb 12;351(6274):664-5. doi: 10.1126/science.aab3907. No abstract available.

PMID:
26912845
20.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ.

Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29.

21.

Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods.

Nam J, Briggs A, Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, Junejo S, Eteiba H, Petrie MC, Lindsay M, Watkins S, Corbett S, O'Rourke B, O'Donnell A, Stewart A, Hannah A, McConnachie A, Henderson R, Berry C.

Cost Eff Resour Alloc. 2015 Nov 14;13:19. doi: 10.1186/s12962-015-0045-9. eCollection 2015.

22.

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J.

Lancet Oncol. 2015 Nov;16(15):1556-1568. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22.

PMID:
26482278
23.

Photoacoustic and ultrasound imaging using dual contrast perfluorocarbon nanodroplets triggered by laser pulses at 1064 nm.

Hannah AS, VanderLaan D, Chen YS, Emelianov SY.

Biomed Opt Express. 2014 Aug 14;5(9):3042-52. doi: 10.1364/BOE.5.003042. eCollection 2014 Sep 1.

24.

Right ventricular septal pacing as alternative for failed left ventricular lead implantation in cardiac resynchronization therapy candidates.

Alhous MH, Small GR, Hannah A, Hillis GS, Frenneaux M, Broadhurst PA.

Europace. 2015 Jan;17(1):94-100. doi: 10.1093/europace/euu259. Epub 2014 Oct 30.

PMID:
25359384
25.

A novel technique for accurate Poller (blocking) screw placement.

Hannah A, Aboelmagd T, Yip G, Hull P.

Injury. 2014 Jun;45(6):1011-4. doi: 10.1016/j.injury.2014.02.029. Epub 2014 Feb 28.

PMID:
24629702
26.

A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy.

Adam M, Hannah A, Budäus L, Steuber T, Salomon G, Michl U, Haese A, Fisch M, Wittmer C, Steurer S, Minner S, Heinzer H, Huland H, Graefen M, Sauter G, Schlomm T, Isbarn H.

J Urol. 2014 Jul;192(1):97-101. doi: 10.1016/j.juro.2014.01.029. Epub 2014 Feb 8.

PMID:
24518778
27.

Indocyanine green-loaded photoacoustic nanodroplets: dual contrast nanoconstructs for enhanced photoacoustic and ultrasound imaging.

Hannah A, Luke G, Wilson K, Homan K, Emelianov S.

ACS Nano. 2014 Jan 28;8(1):250-9. doi: 10.1021/nn403527r. Epub 2013 Dec 18.

28.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group.

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.

PMID:
24095299
29.

Comparison of sample types for N-terminal pro-B-type natriuretic peptide measured on the Siemens Immulite 2500 and Dimension Vista LOCI methods.

Peake RW, Turner HE, Leaper W, Deans KA, Hannah A, Croal BL.

Ann Clin Biochem. 2012 Sep;49(Pt 5):494-6. doi: 10.1258/acb.2012.012053. Epub 2012 Aug 15.

PMID:
22896660
30.

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.

Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, Zhong Z, Ma W, Hudis C, Modi S.

Clin Cancer Res. 2012 Sep 15;18(18):5090-8. doi: 10.1158/1078-0432.CCR-11-3200. Epub 2012 Jul 10.

31.

Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme.

Stahla-Beek HJ, April DG, Saeedi BJ, Hannah AM, Keenan SM, Geiss BJ.

J Virol. 2012 Aug;86(16):8730-9. doi: 10.1128/JVI.00384-12. Epub 2012 Jun 6.

32.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.

Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian C.

Invest New Drugs. 2012 Dec;30(6):2294-302. doi: 10.1007/s10637-011-9765-7. Epub 2011 Nov 10. Erratum in: Invest New Drugs. 2012 Dec;30(6):2450. Miranov, Svetlana [corrected to Mironov, Svetlana].

33.

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.

Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MA.

Cancer Chemother Pharmacol. 2012 Feb;69(2):523-31. doi: 10.1007/s00280-011-1724-7. Epub 2011 Aug 27.

34.

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.

Monk JP, Villalona-Calero M, Larkin J, Otterson G, Spriggs DS, Hannah AL, Cropp GF, Johnson RG, Hensley ML.

Invest New Drugs. 2012 Aug;30(4):1676-83. doi: 10.1007/s10637-011-9731-4. Epub 2011 Aug 9.

35.

A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development.

Geiss BJ, Stahla-Beek HJ, Hannah AM, Gari HH, Henderson BR, Saeedi BJ, Keenan SM.

J Biomol Screen. 2011 Sep;16(8):852-61. doi: 10.1177/1087057111412183. Epub 2011 Jul 25.

36.

Impact of temporary right ventricular pacing from different sites on echocardiographic indices of cardiac function.

Alhous MH, Small GR, Hannah A, Hillis GS, Broadhurst P.

Europace. 2011 Dec;13(12):1738-46. doi: 10.1093/europace/eur207. Epub 2011 Jul 14.

PMID:
21764814
37.

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.

Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10.

38.

Boys must be men, and men must have sex with women: a qualitative CBPR study to explore sexual risk among African American, Latino, and White gay men and MSM.

Rhodes SD, Hergenrather KC, Vissman AT, Stowers J, Davis AB, Hannah A, Alonzo J, Marsiglia FF.

Am J Mens Health. 2011 Mar;5(2):140-51. doi: 10.1177/1557988310366298. Epub 2010 Apr 21.

39.

A study to evaluate the accuracy of ultrasound in the diagnosis of parotid lumps and to review the sonographic features of parotid lesions - results in 220 patients.

Sriskandan N, Hannah A, Howlett DC.

Clin Radiol. 2010 May;65(5):366-72. doi: 10.1016/j.crad.2010.01.009. Epub 2010 Feb 25.

PMID:
20380934
40.

Focus on flaviviruses: current and future drug targets.

Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM.

Future Med Chem. 2009 May;1(2):327-44. doi: 10.4155/fmc.09.27. Review.

41.

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.

Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR.

Leukemia. 2010 Apr;24(4):699-705. doi: 10.1038/leu.2009.292. Epub 2010 Jan 28.

PMID:
20111068
42.

Patient aggression perceived by community support workers.

Gale C, Hannah A, Swain N, Gray A, Coverdale J, Oud N.

Australas Psychiatry. 2009 Dec;17(6):497-501.

PMID:
20001375
43.

Evolution of allometry in antirrhinum.

Feng X, Wilson Y, Bowers J, Kennaway R, Bangham A, Hannah A, Coen E, Hudson A.

Plant Cell. 2009 Oct;21(10):2999-3007. doi: 10.1105/tpc.109.069054. Epub 2009 Oct 30.

44.

Clinical correlation of circulating heat shock protein 70 in acute leukemia.

Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M.

Leuk Res. 2010 May;34(5):605-9. doi: 10.1016/j.leukres.2009.09.014. Epub 2009 Oct 1.

45.

Emotional intelligence and clinical interview performance of dental students.

Hannah A, Lim BT, Ayers KM.

J Dent Educ. 2009 Sep;73(9):1107-17.

46.

Food-the way to a man's heart: a mini-case series of Campylobacter perimyocarditis.

Turpie DF, Forbes KJ, Hannah A, Metcalfe MJ, McKenzie H, Small GR.

Scand J Infect Dis. 2009;41(6-7):528-31. doi: 10.1080/00365540902913486.

PMID:
19396664
47.

Medical students' experiences of patient aggression and communication style.

Mackay J, Hannah A, Gale C.

Australas Psychiatry. 2009 Feb;17(1):59-60. No abstract available.

PMID:
19145715
48.

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.

Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M.

Leuk Res. 2009 Feb;33(2):212-7. doi: 10.1016/j.leukres.2008.07.012. Epub 2008 Aug 19.

49.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.

J Clin Oncol. 2007 Dec 1;25(34):5410-7.

PMID:
18048823
50.

A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.

Bareng J, Jilani I, Gorre M, Kantarjian H, Giles F, Hannah A, Albitar M.

Leuk Lymphoma. 2007 Nov;48(11):2189-95.

PMID:
17926180

Supplemental Content

Loading ...
Support Center